• Explore /
  • Poster
  • / RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.

RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.

Abstract Poster

Authors

null

Li Zhou

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China

Li Zhou , Huayan Xu , Xieqiao Yan , Zhihong Chi , Chuanliang Cui , Lu Si , Bixia Tang , Lili Mao , BIN LIAN , Xuan Wang , Siming Li , Xue Bai , Jun Guo , Xinan Sheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT04264936

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4534)

DOI

10.1200/JCO.2021.39.15_suppl.4534

Abstract #

4534

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Li Zhou

First Author: Xinan Sheng

First Author: Rui-hua Xu

First Author: Rui-hua Xu